SolAeroMed 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
2 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
carbon dioxide/perflubron (S1226) / SolAeroMed
NCT03903913: Safety, Tolerability and Efficacy of S-1226 in Cystic Fibrosis and Non CF Bronchiectasis

Recruiting
2a
12
Canada
S-1226, S-1226 (4%), S-1226 (8%), S-1226 (12%)
SolAeroMed Inc.
Cystic Fibrosis, Bronchiectasis
02/22
08/22
SAMi-06-1-01, NCT04949386: Safety, Tolerability and Efficacy of S-1226 in Post-COVID-19 Subjects With Persistent Respiratory Symptoms.

Not yet recruiting
2
48
NA
S-1226 (8%), S-1226, Placebo
SolAeroMed Inc.
Post Acute COVID-19 Syndrome, Long COVID, COVID-19 Respiratory Infection
12/21
01/22
carbon dioxide/perflubron device (S1226 device) / SolAeroMed
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
carbon dioxide/perflubron (S1226) / SolAeroMed
NCT03903913: Safety, Tolerability and Efficacy of S-1226 in Cystic Fibrosis and Non CF Bronchiectasis

Recruiting
2a
12
Canada
S-1226, S-1226 (4%), S-1226 (8%), S-1226 (12%)
SolAeroMed Inc.
Cystic Fibrosis, Bronchiectasis
02/22
08/22
SAMi-06-1-01, NCT04949386: Safety, Tolerability and Efficacy of S-1226 in Post-COVID-19 Subjects With Persistent Respiratory Symptoms.

Not yet recruiting
2
48
NA
S-1226 (8%), S-1226, Placebo
SolAeroMed Inc.
Post Acute COVID-19 Syndrome, Long COVID, COVID-19 Respiratory Infection
12/21
01/22
carbon dioxide/perflubron device (S1226 device) / SolAeroMed
No trials found

Download Options